Affordable Access

An IL-7 fusion protein that shows increased thymopoietic ability.

The Journal of Immunology
The American Association of Immunologists
Publication Date
  • Biology
  • Medicine


The role of IL-7 during thymopoiesis has led to it being the focus of a number of therapeutic interventions. However, its small size and pleiotropic nature present problems for thymus-directed therapies. We have created a fusion molecule between the extracellular N-terminal domain of CCR9 and IL-7, which has the potential to overcome these difficulties. This novel fusion protein retains the thymopoietic activity of IL-7 and the ligand-binding ability of CCR9. As a thymopoietic agent, compared with IL-7, it shows an enhanced retention in the thymus, increased de novo T cell production, and increased thymic output. Old mice receiving the fusion protein show improved CD8 T cell responses and reduced viral load after infection with influenza virus compared with those receiving IL-7. This chimeric molecule offers a novel therapeutic strategy that may result in the production of an effective immunorestorative agent.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times

More articles like this

An IL-7 fusion protein that shows increased thymop...

on The Journal of Immunology Sep 15, 2005

A B7.1-antibody fusion protein retains antibody sp...

on The Journal of Immunology Apr 01, 1998

An IgG3-IL2 fusion protein activates complement, b...

on Immunotechnology : an internat... August 1995
More articles like this..